Epidyolex Update
The National Centre for Pharmacoeconomics (NCPE) have issued their recommendation to the HSE regarding the reimbursement of Epidyolex.
Epidyolex is a cannabidiol (CBD) medication which through clinical trials has been shown to have a positive impact in the treatment of two rare epilepsies – namely Lennox Gastaut Syndrome & Dravet Syndrome.

We are delighted to have been listed as a local patient partner in the development of a National Public & Patient Involvement (PPI) Network.